VanEck Vectors Coal ETF KOL
Set alert
94.92 USD 0.00 0.00%
As of Dec 14, 3:59 PM ET
94.90 Day range 95.50
54.10 52-week range 99.33
- Open
- 95.03
- Prev close
- 94.92
- Mkt cap
- 35.33M
- Vol
- 56.46K
- Avg vol
- 8.23K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 94.90
- High
- 95.50
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 94.92
- 200-d avg
- 81.72
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 94.92
- 200-day average
- 81.72
About VanEck Vectors Coal ETF
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® Global Coal Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes companies in the global coal industry that generate at least 50% of their revenues from coal operation (production, mining and cokeries), transportation of coal, production of coal mining equipment as well as from storage and trade. It is non-diversified.
News
- Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
- enGene to Host KOL Webinar on October 15, 2026
- vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
- Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
- Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
- Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
- Spectral AI Showcases DeepView® System for Burn Indication and KOL Research at Southern Regional Burn Conference
- Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
- Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
- Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Your note
Sign in to keep a note on KOL — it syncs with the Stock Master app.